| Nephrotic Syndrome
Rayos vs Furoscix
Side-by-side clinical, coverage, and cost comparison for nephrotic syndrome.Deep comparison between: Rayos vs Furoscix with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFuroscix has a higher rate of injection site reactions vs Rayos based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Furoscix but not Rayos, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rayos
Furoscix
At A Glance
Oral
Daily
Corticosteroid
SC injection
Loop diuretic
Indications
- Dermatitis, Atopic
- Allergic rhinitis (disorder)
- Serum Sickness
- Dermatitis Herpetiformis
- Contact Dermatitis
- Exfoliative dermatitis
- Mycosis Fungoides
- Pemphigus
- Erythema Multiforme
- Congenital Adrenal Hyperplasia
- Hypercalcemia
- thyroiditis; nonsuppurative
- Adrenal gland hypofunction
- Crohn Disease
- Ulcerative Colitis
- Autoimmune hemolytic anemia
- Anemia, Diamond-Blackfan
- Immune thrombocytopenic purpura
- Pure Red-Cell Aplasia
- Acute leukemia
- Lymphoma, Non-Hodgkin
- Multiple Sclerosis
- Cerebral Edema
- Ophthalmia, Sympathetic
- Uveitis
- Chronic Obstructive Airway Disease
- Aspergillosis, Allergic Bronchopulmonary
- Aspiration pneumonitis
- Asthma
- Tuberculosis
- Extrinsic allergic alveolitis
- Bronchiolitis Obliterans Organizing Pneumonia
- Idiopathic eosinophilic pneumonitis
- Idiopathic Pulmonary Fibrosis
- Pneumonia, Lipid
- Sarcoidosis
- Nephrotic Syndrome
- Primary gout
- Ankylosing spondylitis
- Dermatomyositis
- Polymyalgia Rheumatica
- Arthritis, Psoriatic
- Polychondritis, Relapsing
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Lupus Erythematosus, Systemic
- Vasculitis
- Trichinellosis
- Tuberculosis, Meningeal
- Edema
- Chronic heart failure
- Chronic Kidney Diseases
- Nephrotic Syndrome
Dosing
All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.
Edema, Chronic heart failure, Chronic Kidney Diseases, Nephrotic Syndrome 30 mg subcutaneously over the first hour followed by 12.5 mg per hour for the subsequent 4 hours (total 80 mg) via On-body Infusor applied to the abdomen; not for chronic use, replace with oral diuretics as soon as practical.
Contraindications
- Known hypersensitivity to prednisone or any excipient
- Anuria
- History of hypersensitivity to furosemide, any component of the FUROSCIX formulation, or medical adhesives
Adverse Reactions
Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain
Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure
Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone
Serious fluid, electrolyte, and metabolic abnormalities, ototoxicity, anaphylactic or anaphylactoid reactions, aplastic anemia, toxic epidermal necrolysis, Stevens-Johnson syndrome, interstitial nephritis, necrotizing angiitis
Other reported pancreatitis, jaundice, nausea, vomiting, tinnitus, hearing loss, vertigo, dizziness, headache, thrombocytopenia, agranulocytosis, leukopenia, rash, erythema multiforme, orthostatic hypotension, injection site erythema and pain, muscle spasm, restlessness
Pharmacology
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.
Furosemide is a loop diuretic that primarily inhibits sodium and chloride reabsorption in the proximal and distal tubules and the loop of Henle, producing high-degree diuresis independent of carbonic anhydrase inhibition or aldosterone.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rayos
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
Furoscix
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Rayos
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Furoscix
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Rayos
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Furoscix
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Rayos.
No savings programs available for Furoscix.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FuroscixView full Furoscix profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.